Skip to content
Tell Me About Peptides

storage questions

How Long Does a Reconstituted Peptide Last?

The dry vial and the dissolved one are not two settings of the same clock. Once a peptide is in solution the limiting chemistry changes, the diluent starts to matter more than almost anything else, and the widely quoted single figure turns out to have come from somewhere else entirely.

This is the other half of a question answered elsewhere on this site. The dry shelf-life piece deals with how long a freeze-dried powder keeps; this one starts at the point where water has been added and the powder has stopped being a powder. The two are not two settings of the same clock, and treating them as though they were is the commonest way people end up quoting a figure that was never about their material.

The direct answer is that a solution keeps for far less time than the dry vial did, and that how much less depends heavily on what it was dissolved in. Dissolving a peptide surrounds it with the reactant that freeze-drying had removed, so the chemistry that had been suppressed simply resumes 12. Everything after that is a question of which additional variables are now in play.

The diluent is the largest of them, and the distinction that actually matters is whether it contains an antimicrobial preservative. That single difference changes what limits the container's usable life — and, importantly, it changes it for a reason that has nothing to do with the peptide's chemistry.

A long horizontal bar and, well below it, a much shorter bar divided into five small segments, both drawn in deep teal on an off-white field.
Not two settings of one clock. The second interval is far shorter, and it is spent in segments — each entry into the container is part of what consumes it.

Why does a peptide in solution keep so much worse than the powder?

Because water is not a neutral container for peptide chemistry — it takes part in the reactions that destroy peptides. Freeze-drying works by removing a reactant, and dissolving the cake puts that reactant back at full strength 12.

The two routes that dominate both consume water. The peptide backbone can be hydrolysed, cutting the chain. Certain residues, asparagine and glutamine in particular, rearrange through a hydrolytic mechanism that changes the molecule without breaking it apart. Both proceed at a rate that collapses in a dry solid and recovers immediately in solution 1.

A second thing changes at the same moment, and it is less often mentioned. In a dry cake, molecular mobility is very low; molecules cannot easily move to meet one another. In solution they can, which opens routes that need two molecules rather than one — chief among them aggregation, where peptide molecules associate into assemblies that do not come apart again 12.

Then the list of variables lengthens. Backbone cleavage and residue rearrangement are both strongly pH-dependent, so the same compound degrades at measurably different rates in different buffers. Dissolved oxygen and trace metal ions drive oxidation of the susceptible residues 5. Even the vessel counts: peptides adsorb to container surfaces, which removes material from solution with no chemical change at all 1.

So the shift from powder to solution is not a change of degree along one axis. It restarts a suppressed set of reactions and adds several new variables at once, which is why the honest answer to the headline question begins with a much shorter interval and then immediately asks what the solution consists of.

Does the diluent change how long it lasts?

Yes, and it is the largest single variable anyone has control over. The relevant distinction is whether the diluent contains an antimicrobial preservative, and it changes what limits the container rather than how fast the peptide degrades.

A preserved diluent contains a compound whose function is to suppress microbial growth in a container that will be opened more than once — benzyl alcohol is the long-standing example in parenteral products, and the practice of including one exists specifically because a multidose container is entered repeatedly and each entry is an opportunity for contamination 3. An unpreserved diluent contains no such component, so once the closure has been breached nothing is holding growth back, and the in-use period contemplated for such a container is correspondingly short 4.

Here is the part that gets conflated constantly. A preservative acts on microbiology. It does nothing whatever about hydrolysis, deamidation, oxidation or aggregation, which proceed at exactly the rate the temperature, pH and sequence dictate regardless of what is holding the bacteria off 13. A preserved solution has a longer microbiological life. Its peptide is not more chemically durable by a single day.

In some cases the preservative is actively unhelpful to the protein. Preservatives are small amphiphilic molecules, and several are known to promote aggregation of proteins in solution — an effect well enough established that it forms part of the routine formulation trade-off when a multidose presentation is being developed 3. Preservation is a compromise that gets made deliberately, not a free improvement.

FactorWhat it acts onWhat it leaves untouched
An antimicrobial preservativeMicrobial growth in a container opened more than onceHydrolysis, deamidation, oxidation and aggregation of the peptide
Cold storageThe rate of every chemical route at onceContamination introduced at the closure
Exclusion of lightPhoto-oxidation of a few susceptible residuesEverything that proceeds in the dark, which is most of it
Fewer entries into the containerCumulative contamination and ingress of oxygenChemistry already under way in the solution
A stated in-use period on an approved productWhat was demonstrated for that formulation in that containerAny compound whose formulation was not the one tested
What each control acts on once a peptide is in solution, and what it leaves entirely untouched.

Where does the 28-day figure come from?

From in-use stability practice for multidose injectable medicines, and from nothing that was ever measured on a research peptide. It is a borrowed number, and knowing where it was borrowed from is most of what makes it usable.

European guidance on in-use stability sets out how the period after first opening is established for a product supplied in a multidose container. The manufacturer holds the opened product under the conditions it will actually meet in use, samples it across the intended period, and tests it against specification — chemical, physical and microbiological — at the end. The declared in-use period is the output of that testing 4.

Twenty-eight days became a convention because it is the interval a great many preserved multidose products are tested to and labelled with. It is a period that suits the way such products are used and that preserved formulations can generally be demonstrated to hold. It is, in other words, an empirical result repeated often enough to look like a rule 4.

What it is not is a property of peptides. The figure belongs to specific formulations in specific containers, each of which was tested. Transferring it to an uncharacterised research compound, in an unknown buffer, at an unknown pH, in a container nobody has assessed, is taking the answer from one experiment and applying it to a different one 24.

That does not make it a bad reference point, provided it is understood as one. It is a reasonable order of magnitude for a preserved aqueous solution held cold, and a plainly optimistic one for an unpreserved solution. The mistake is only ever in treating it as a measurement rather than a convention.

What else shortens it — temperature, light, repeated access?

All three, and each acts on something different. Temperature is the broadest lever, light is a narrow and sequence-specific one, and repeated access is the one that accumulates quietly.

Temperature acts on every route at once, because degradation is chemistry and chemical rates fall as temperature falls 2. That makes cold storage genuinely useful and completely unspecific — it slows hydrolysis, deamidation, oxidation and aggregation together, without addressing any of them in particular. It also does nothing at all about contamination already introduced.

Light acts only on the residues that can absorb it or that reactive species generated by it can reach — the aromatic residues and the sulfur-containing ones, principally 5. In solution the exposure is more meaningful than in a dry cake, because both light and dissolved oxygen are present and molecules can move. Whether it matters at all for a given compound depends on its sequence, which is covered separately on this site.

Repeated access is the underrated one. Each entry into a container introduces the possibility of contamination, admits a little more oxygen to a solution where oxidation is already a route, and gives peptide molecules another pass at the container surface they adsorb to 13. None of these is dramatic on any single occasion. All of them are cumulative, and the count is rarely recorded.

Behind all three sits the reason no single number covers every compound. The quantity being asked about depends on at least six variables, and one figure discards all of them: sequence, pH, buffer composition, temperature, dissolved oxygen and container surface each move the answer, and they do not move it by small amounts 12.

Sequence alone is enough to separate two compounds decisively. A peptide containing methionine has an oxidation route available that one without it does not 5. A sequence with asparagine next to glycine carries a rearrangement that is much faster than the same reaction elsewhere in the same chain. Two compounds of similar length, in the same buffer, at the same temperature, can behave very differently over the same week.

This is why a stated figure without its conditions attached is not a measurement. The useful response to one is a set of questions: which peptide, at what pH, in what buffer, at what temperature, in what container. With those attached, a number is a result. Without them it is a rule of thumb wearing the clothes of one 1.

For research material the situation is starker still, and worth stating plainly rather than dressing up. An approved multidose medicine has an in-use period because somebody ran the study 4. A research compound has none, because nobody did. The interval anyone quotes for it is inference from general chemistry, which is a legitimate thing to reason with and a different thing from data.

So how long does a reconstituted peptide last?

Much less time than the dry vial, with the diluent setting the outer bound and the chemistry setting the inner one. A preserved solution held cold can support a meaningfully longer in-use period than an unpreserved one, because the preservative addresses the microbiological limit that would otherwise bite first 34. The peptide's own chemical clock is unaffected by that and continues running throughout.

Which means the two limits should be thought about separately rather than collapsed into one figure. The microbiological limit is what a preservative and a container are for. The chemical limit is what temperature, pH, oxygen, light and sequence determine, and it is the one that produces no visible sign as it approaches 25.

The honest summary is that there is no number here that belongs to the word "peptides", only numbers that belong to particular compounds in particular solutions — and that the widely repeated one came from a body of testing performed on something else. Knowing that is not a smaller answer than the number. It is a more useful one, because it tells you which question to ask about the material actually in front of you.

References

  1. Instability, stabilization, and formulation of liquid protein pharmaceuticalsInternational Journal of Pharmaceutics, 1999
  2. Stability of protein pharmaceuticals: an updatePharmaceutical Research, 2010
  3. Antimicrobial preservative use in parenteral products: past and presentJournal of Pharmaceutical Sciences, 2007
  4. Note for Guidance on In-Use Stability Testing of Human Medicinal Products (CPMP/QWP/2934/99)European Medicines Agency, 2001
  5. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilizationBiotechnology and Bioengineering, 1995